In terms of prior therapies, most patients in both the trastuzumab deruxtecan and T-DM1 arms had received prior treatment with trastuzumab (Herceptin; 99.6% vs 99.6% and pertuzumab (Perjeta; 62.1% vs 60.1%). Patients underwent a median of 2 (range, 0-1...
advanced breast cancer. Those data were already published, and there was a significant improvement in the [progression-free survival (PFS)] for treatment with trastuzumab deruxtecan. This treatment also significantly improved response rates compared with the control...
Trastuzumab deruxtecan significantly prolonged PFS compared with ado-trastuzumab emtansine among patients with HER2-positive metastatic breast cancer, topline data of a randomized phase 3 trial showed. Patients with HER2-positive metastatic breast cancer who undergo initial treatment with trastuzumab (Herce...
Patients with advanced HER2-positive breast cancer had improved progression-free and overall survival when treated with trastuzumab deruxtecan compared with capecitabin-based treatment, according to recent findings. Trastuzumab deruxtecan (T-DXd) led to a 34% reduction i...
In terms of prior therapies, most patients in both the trastuzumab deruxtecan and T-DM1 arms had received prior treatment with trastuzumab (Herceptin; 99.6% vs 99.6% and pertuzumab (Perjeta; 62.1% vs 60.1%). Patients underwent a median of 2 (range, 0-16) prior lines of therapy ...
在早期临床试验中,以ravtansine为基础的ADCs与卡铂或阿霉素联合治疗对铂敏感和耐药的卵巢癌患者,以及以deruxtecan为基础的ADCs与卡培他滨或顺铂联合治疗胃癌和肺癌患者的疗效显著。 给药时间的设计 给药时间可能与药物组合设计相关。微管蛋白聚合是ADC内吞机制的关键组成部分,DNA损伤介导的G2/M期阻滞可能需要一些时间...
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial Article Open access 02 June 2024 Background Between 15 and 20% of all breast cancers overexpress human epidermal growth factor receptor 2 (HER2)....
(another humanized monoclonal antibody that binds to the domain II of HER2) as the first-line therapy for metastatic HER2-positive breast cancer by the FDA in 2012 [15], more potent trastuzumab-based drugs like antibody–drug conjugates (ADCs) (trastuzumab deruxtecan [T-DXd] and trastuzumab ...
The Importance of Trastuzumab Deruxtecan in HER2+ Breast Cancer Treatment Sara A. Hurvitz, MD March 1st 2023 Podcast In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzu...
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. PMID: 28215665Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. PMID: 32213540...